-
1Academic Journal
Συγγραφείς: E. D. Kuzminykh, V. M. Lebedev, V. E. Senchenko, M. S. Cherepyansky, V. A. Gonchar, D. S. Korobko, Е. Д Кузьминых, В. М. Лебедев, В. Е. Сенченко, М. С. Черепянский, В. А. Гончар, Д. С. Коробко
Συνεισφορές: The article is sponsored by Novartis., Статья спонсируется компанией «Новартис»
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 17, No 1 (2025); 72-77 ; Неврология, нейропсихиатрия, психосоматика; Vol 17, No 1 (2025); 72-77 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2025-1
Θεματικοί όροι: анти-CD20-терапия, pediatric multiple sclerosis, multiple sclerosis, anti-CD20 monoclonal antibody, anti-CD20 therapy, педиатрический рассеянный склероз, рассеянный склероз, анти-CD20 моноклональные антитела
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2450/1776; Ghezzi A. Old and New Strategies in the Treatment of Pediatric Multiple Sclerosis: A Personal View for a New Treatment Approach. Neurol Ther. 2024 Aug;13(4):949-63. doi:10.1007/s40120-024-00633-6. Epub 2024 Jun 1.; Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature. J Child Neurol. 2019 Oct;34(12):705- 12. doi:10.1177/0883073819845827. Epub 2019 Jun 11.; Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010 May;9(5):520-32. doi:10.1016/S1474-4422(10)70064-8; Клинические рекомендации «Рассеянный склероз» 2022. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/739_1 (дата обращения 20.08.2024).; Ghezzi A, Amato MP, Makhani N, et al. Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology. 2016 Aug 30;87(9 Suppl 2):S97- S102. doi:10.1212/WNL.0000000000002823. Erratum in: Neurology. 2016 Nov 8;87(19):2068. doi:10.1212/WNL.0000000000003369; Benallegue N, Rollot F, Wiertlewski S, et al; OFSEP (Observatoire Francais de la Sclerose en Plaques) Investigators. Highly Effective Therapies as First-Line Treatment for PediatricOnset Multiple Sclerosis. JAMA Neurol. 2024 Mar 1;81(3):273-82. doi:10.1001/jamaneurol.2023.5566; Yearwood C, Wilbur C. Trends in the Epidemiology and Treatment of Pediatric-Onset Multiple Sclerosis in Alberta, Canada. J Child Neurol. 2023 Apr;38(5):321-8. doi:10.1177/08830738231176588; Pröbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Jun;38(2):251-8. doi:10.1097/WNO.0000000000000642; Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of antiCD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024 Apr;271(4):1515-35. doi:10.1007/s00415-023-12007-3; Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019 Mar 14;7(1):20. doi:10.3390/biomedicines7010020; Mayrhofer P, Kunert R. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Hum Antibodies. 2019;27(1):37-51. doi:10.3233/HAB-180347; Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. doi:10.3389/fimmu.2022.814064; Инструкция по применению лекарственного препарата Бонспри® (ОХЛП) ЛП-№(001332)-(РГ-RU)-251022. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7979032db214-4fa5-b9f2-f1731148f509 (дата обращения 20.11.2024).; Skataric M, Savelieva M, Pigeolet E, Leppert D. Ofatumumab Dose Selection in Pediatric Population with Relapsing Multiple Sclerosis. Abstract Т-090 for the Ninth American Conference on Pharmacometrics (ACoP9). J Pharmacokinet Pharmacodyn. 2018;45(Suppl 1):3-134. doi:10.1007/s10928-018-9606-9; ClinicalTrials.gov Identifier: NCT04926818. Available at: https://clinicaltrials.gov/ct2/show/NCT04926818; Gärtner J, Deiva K, Graves J, et al. Innovative Phase 3 NEOS Study Design Evaluating Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Paediatric Multiple Sclerosis. Poster 102. Poster presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 13–15 October 2021. Available at: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2021/posters/P102_E CTRIMS2021.pdf (accessed 20.09.2024).; National Multiple Sclerosis Society Pediatric MS. Available at: https://www.nationalmssociety.org/For-Professionals/ClinicalCare/Managing-MS/Pediatric-MS; Margoni M, Rinaldi F, Perini P, Gallo P. Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities. Front Neurol. 2021 May 17;12:676095. doi:10.3389/fneur.2021.676095; Проект Клинических рекомендаций «Рассеянный склероз» от 2024 (МАВРС). Доступно по ссылке: https://mapcms.ru/projects/recommendations/proekty-klinicheskikhrekomendatsiy/ (дата обращения 20.08.2024).; Maillart E, Renaldo F, Papeix C, et al. Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 25;7(3):e683. doi:10.1212%2FNXI.0000000000000683; Sedani S, Absoud M, Milford D, et al. Good response to Ofatumumab in a child with severe relapsing Neuromyelitis Optica. P675. Mult Scler J. 2012;18:(S4):279-508. doi:10.1177/1352458512459021; Gou B, Yang P, Feng J, et al. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab. J Neuroimmunol. 2023 Mar 15;376:578035. doi:10.1016/j.jneuroim.2023.578035; Hiya S, Yoshimura H, Kawamoto M. Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoproteinimmunoglobulin G-associated disease (MOGAD). eNeurologicalSci. 2023 Apr 6;31:100461. doi:10.1007/s10928-018-9606-9; Bar-Or A, Wiendl H, Montalban X, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910-24. doi:10.1177/13524585211044479; Hauser SL, Bar-Or A, Cohen JA, et al.; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-57. doi:10.1056/NEJMoa1917246.
-
2Academic Journal
Συγγραφείς: E. V. Popova, Е. В. Попова
Συνεισφορές: This article has been supported by Novartis, Статья спонсируется компанией «Новартис»
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 6 (2023); 142-145 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 6 (2023); 142-145 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-6
Θεματικοί όροι: анти-CD20-терапия, ofatumumab, monoclonal antibody, anti-CD20, офатумумаб, моноклональное антитело
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/2151/1618; Pröbstel AK, Hauser SL. Multiple Sclerosis: B Cells Take Center Stage. J Neuroophthalmol. 2018 Jun;38(2):251-8. doi:10.1097/WNO.0000000000000642; Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J. 2008 Oct;3(9-10):1157-71. doi:10.1002/biot.200800110; Frisch ES, Pretzsch R, Weber MS. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20 – Yet Progress Continues. Neurotherapeutics. 2021 Jul;18(3):1602-22. doi:10.1007/s13311-02101048-z. Epub 2021 Apr 20.; Klein C, Lammens A, SchКfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb;5(1):22-33. doi:10.4161/mabs.22771. Epub 2012 Dec 4.; Hauser SL, Bar-Or A, Cohen JA, et al. B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis from the Pooled Phase 3 ASCLEPIOS I and II Trials. AAN 2020. Poster Session: P7.1-013; Kappos L, Bar-Or A, Cohen JA, et al. Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials. Annual Meeting of the American Academy of Neurology, 2020.; Hauser SL, Bar-Or A, Cohen JA, et al; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):54657. doi:10.1056/NEJMoa1917246; Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology. 2018 Jun 12;90(24):e2107-e2118. doi:10.1212/WNL.0000000000005685. Epub 2018 May 16.; Samjoo IA, Drudge C, Walsh S, et al. Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. J Comp Eff Res. 2023 Jul;12(7):e230016. doi:10.57264/cer-2023-0016. Epub 2023 Jun 2.; Chen C, Zhang E, Zhu C, et al. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):8-22.e23. doi:10.1016/j.japh.2022.07.009. Epub 2022 Aug 1.; Hennessy B, Zierhut ML, Kracker H, et al. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate. Mult Scler Relat Disord. 2022 Aug;64:103908. doi:10.1016/j.msard.2022.103908. Epub 2022 May 23.; Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs Teriflunomide in Relapsing Multiple Sclerosis: Analysis of No Evidence of Disease Activity (NEDA-3) from ASCLEPIOS I and II Trials. Presented at EAN 2020. LB62. Abstracts_LB_210x276_V2.pdf (ean.org). Available from: https://www.ean.org/fileadmin/ user_upload/ean/congress-2020/Present/Abstracts/Abstracts_LB_210x276_V2.pdf; De Seze J, Bar-Or A, Correale J, et al. Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials. Presented at EAN 2020. LB82; Smith P et al. Poster P401 presented at ECTRIMS 2016.; Smith P et al. Oral presentation S24-003 presented at AAN 2017.; Theil D et al. Poster P657 presented at ECTRIMS 2017.; Graham G et al. Poster P0396 presented at ACTRIMSECTRIMS 2020.; Savelieva M et al. Poster EP1624 presented at ECTRIMS 2017.; Ocrelizumab [prescribing information]. South San Francisco, CA: Genentech; March 2017.; Rituximab [summary of product characteristics]. Germany: Roche; February 2020.; Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064. doi:10.3389/fimmu.2022.814064; Wu F, Bhansali SG, Law WC, et al. Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res. 2012 Jul;29(7):1843-53. doi:10.1007/s11095-012-0708-6; Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012 Sep;14(3):559-70. doi:10.1208/s12248-0129367-0. Epub 2012 May 23.; Migotto MA et al. P3.406 presented at AAN 2018.; Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019 Nov;36(11):2986-96. doi:10.1007/s12325-01901101-6. Epub 2019 Oct 5.; Benedetti MS, Whomsley R, Poggesi I, et al. Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009;41(3):344-90. doi:10.1080/10837450902891295; Bigaud M, Anthony D, Lutzenburg P, et al. Comparative Pharmacology of Ofatumumab versus Ocrelizumab in Humanised-CD20 Transgenic Mice. Presented at ECTRIMS 2022. P298. Available from: https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2022/Abstr acts/P298_Abstract.pdf; Hauser S et al. AAN 2022. Oral presentation S14.004.; Sacca F et al. EAN 2022. Oral presentation. OPR134.; Sacca F et al. Poster presented at ЕAN 2023; EPO-642.; Инструкция по медицинскому применению препарата офатумумаб ЛП-№ (001332)(РГ-RU) от 25.10.2022. Доступно по ссылке: https://grls.rosminzdrav.ru/grls (дата обращения 03.11.2022).; Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167. doi:10.3390/vaccines10122167